MA-QUANTORI
8.9.2021 06:02:11 CEST | Business Wire | Press release
Quantori , a leading global provider of end-to-end software engineering, scientific informatics, data sciences and digital transformation services for life science and healthcare companies, today announced the appointment of Solman Rahman to Executive Vice President, Europe to support Quantori’s aggressive growth strategy and strengthen its market position as a premier global services provider.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210907005840/en/
“Solman’s wealth of experience in building and scaling business operations for leading technology consulting and digital platform engineering companies serving the European life science and healthcare markets makes him uniquely positioned to lead Quantori’s expansion in this key region,” said Richard Golob, CEO, Quantori. “Europe continues to be a powerhouse of world-class life science and biopharma industry innovation. We look forward to working with Solman in developing strategic client relationships to help biopharma and life science companies deliver critical technology programs and data management imperatives to accelerate development of novel therapeutics."
As Quantori’s Executive Vice President for Europe, Solman will be responsible for developing key partnerships within the EU region’s ecosystem of pharma and healthcare companies, in addition to ensuring delivery of superior services and providing leading technology capabilities to Quantori’s clients. Solman joins Quantori from EPAM Systems where he led the Northern Europe business and where he previously worked with Quantori leadership, including Richard Golob, who led EPAM’s Global Life Sciences Business into the fastest growing unit at EPAM, in addition to Dr. Yuriy Gankin, Quantori’s Chief Scientific Officer, and Vitaliy Aronov, Quantori’s Chief Technology Officer.
“I am thrilled to be rejoining such a brilliant executive team at a very exciting time in Quantori’s growth and development, especially as the European biopharma industry is scaling the use of digital technologies to enable the provision of precision medicines and personalized healthcare,” said Solman. “A major challenge in working with IT outsourcing companies is that they have a limited understanding of the life sciences and healthcare industries. One of Quantori’s key differentiators is its extensive domain knowledge underpinned by true scientific depth. This unique combination enables us to add considerable value from the outset and speed-to-market horsepower to the critical focus of today’s biopharma companies – to accelerate the translation of their research and data insights into a pipeline of new medicines.”
Prior to leading EPAM’s Northern European business, Solman worked at Cognizant in several roles, including serving as Head of Strategic Engagements and Industry Practice leadership. Solman began his career as an analyst at Cowen Inc. in the Technology Investment Banking Group, undertaking equity research in the biopharma and high-tech sectors. He currently serves as a board advisor to Conversationly, a digital agency leveraging messaging, automation and AI technologies to promote conversational commerce. He holds MSc and BSc degrees in Economics & Management and Econometrics from the London School of Economics and Political Science.
“We are thrilled to welcome Solman onboard, and he will be instrumental in our efforts to expand operations in Europe to help biopharma leaders bring novel and life-saving therapies to market through the powerful partnership of digital IT and R&D informatics,” said Yuriy Gankin, PhD, Quantori’s Chief Scientific and Strategy Officer.
About Quantori
Quantori
is transforming life sciences and healthcare through the power of digital IT. Quantori develops end-to-end software engineering, scientific informatics, and data science solutions that help biopharma companies accelerate every stage of drug discovery and development. Quantori combines data engineering and advanced analytics with deep scientific domain knowledge to enable life science and healthcare organizations to achieve their digital transformations with greater speed and agility. Learn more about Quantori at www.quantori.com
and connect on social media @Twitter
, @LinkedIn
, and Facebook
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210907005840/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Wyss Geneva Steps Into Its Next Chapter11.6.2026 13:33:00 CEST | Press release
Dr. Tracy Laabs named Director; Prof. Dr. Erwin Böttinger honored for his transformative leadership The Wyss Center for Bio and Neuroengineering in Geneva is pleased to announce the appointment of Dr. Tracy Laabs as Director, effective July 1st 2026. Dr. Laabs succeeds Prof. Dr. Erwin Böttinger, who leaves behind a fundamentally transformed organization: one that no longer just pursues breakthrough science but systematically turns it into ventures that reach patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611328520/en/ Dr. Tracy Laabs, incoming Director, Wyss Center Geneva Since joining the Wyss Center as Director in April 2023, Prof. Böttinger brought a bold vision: to evolve the Center from a portfolio of promising projects into a disciplined engine for venture creation. Under his leadership, the Center spun off six companies in two years (including ABILITY Neurotech SA and Clee Medical SA in 2025) while simult
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit11.6.2026 13:24:00 CEST | Press release
Nearly two-thirds of patients aged 80+ treated with BRUKINSA remained progression-free at six years, despite advanced age and high-risk featuresNew European patient research reveals safety, disease severity, and effectiveness are the top drivers for first-line CLL treatment decisions – not time on therapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor. BRUKINSA is the only BTK inhibitor to demonstrate superior efficacy vs. ibrutinib in a Phase 3 trial.1 These data, one of the largest datasets of older patients with treatment-naive CLL, will be presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden. Amit Agarwal, M.D.,
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations11.6.2026 13:00:00 CEST | Press release
Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis study More than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100) at week 16 – more than 2.5 times the response rate for deucravacitinib Safety profile was consistent with previous studies with no new safety signals identified Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). In the LATITUDE Atlas (TAK-279-PsO-3004) head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib for the primary endpoint, Psoriasis Area and Severity Index (PASI) 100 response rate at week 16. The study also demonstrate
Clearlake Expands Liquid Credit Platform With Acquisition of LCM Asset Management’s CLO Contracts11.6.2026 13:00:00 CEST | Press release
Transaction adds 31 CLOs and more than $5 billion of AUM, strengthening Clearlake Credit’s position in liquid credit Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced that its credit platform, Clearlake Credit, will assume management of CLOs managed by LCM Asset Management, LLC. The transaction adds 31 CLOs representing more than $5 billion of assets under management and increases assets managed by Clearlake Credit to approximately $39 billion across liquid credit, private credit, and other customized credit solutions. The acquisition further broadens the Firm’s capabilities, deepens its relationships with institutional investors, and reinforces its client-centric approach and commitment to seeking attractive risk-adjusted returns across market cycles. Milbank LLP and Dechert LLP represented Clearlake Credit in the transaction
L&T Technology Services, Databricks Partner to Deliver Industrial AI at Scale for Asset-Intensive Industries11.6.2026 12:30:00 CEST | Press release
Partnership brings together LTTS’ expertise in its Sustainability segment and the Databricks platform to accelerate Engineering Intelligence across industrial operations. L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced a strategic go-to-market partnership with Databricks, the leading Data and AI company, to co-develop and deliver Industrial AI solutions that advance Engineering Intelligence (EI) for asset-intensive enterprises. Anchored in LTTS' Sustainability segment, spanning Process Engineering, Discrete Manufacturing and Industrial Products, the partnership will support Energy, Petrochemicals and Industrials clients globally. As industrial organizations seek to unlock greater value from decades of operational and engineering data, the alliance will combine LTTS’ deep domain capabilities with the Databricks platform to transform complex plant data into Engineering Intelligence - enabling improved asset reli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom